Back to Search Start Over

Lamellar liquid crystals maintain keratinocytes' membrane fluidity: An AFM qualitative and quantitative study.

Authors :
Gosenca Matjaž M
Škarabot M
Gašperlin M
Janković B
Source :
International journal of pharmaceutics [Int J Pharm] 2019 Dec 15; Vol. 572, pp. 118712. Date of Electronic Publication: 2019 Oct 05.
Publication Year :
2019

Abstract

Despite extensive investigations of lamellar liquid crystals for dermal application, the effects of these systems at the cellular level are still not well elucidated. The key aim of this study was to determine the elasticity and morphological features of keratinocytes after exposure to a lamellar liquid crystal system (LLCS) using atomic force microscopy (AFM) as the method of choice. Prior to AFM assessment, a cell proliferation test and light plus fluorescence imaging were applied to determine the sub-toxic concentration of LLCS. According to the AFM results, slightly altered morphology was observed in the case of fixed keratinocytes, while an intact morphology was visualized on live cells. From the quantitative study, decreased Young's moduli were determined for fixed cells (i.e., 8.6 vs. 15.2 MPa and 1.3 vs. 2.9 MPa for ethanol or PFA-fixed LLCS-treated vs. control cells, respectively) and live cells (i.e., ranging from 0.6 to 2.8 for LLCS-treated vs. 1.1-4.5 MPa for untreated cells), clearly demonstrating increased cell elasticity. This is related to improved membrane fluidity as a consequence of interactions between the acyl chains of cell membrane phosphatidylcholine and those of LLCS. What seems to be of major importance is that the study confirms the potential clinical relevance of such systems in treatment of aged skin with characteristically more rigid epithelial cells.<br /> (Copyright © 2019. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
1873-3476
Volume :
572
Database :
MEDLINE
Journal :
International journal of pharmaceutics
Publication Type :
Academic Journal
Accession number :
31593808
Full Text :
https://doi.org/10.1016/j.ijpharm.2019.118712